AI Screening Tool for Tardive Dyskinesia Identifies Disorder and Prompts Clinical Evaluation
Key Takeaways
- Follow-up survey data showed 156 TD diagnoses via screening, 125 treatment prescriptions, and 548 patient-provider discussions, suggesting the tool can drive clinical engagement after risk identification.
- Adoption metrics included more than 9400 screenings for 8600 patients and utilization by over 750 providers and organizations, indicating broad feasibility across care settings.
AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.
Videra Health’s video-based AI screening tool, TDScreen, was able to identify symptoms of
Over 2000 patients completed a follow-up survey after using TDScreen, where 156 patients received a tardive dyskinesia diagnosis and 125 were ultimately prescribed treatment. Overall, 548 patients discussed the results of the screening with their provider. Since the launch of the assessment, over 9400 screenings for 8600 patients have been conducted, and over 750 providers and organizations have used the tool.
"What we are seeing with TDScreen is real-world validation that identifying TD risk earlier can prompt patients to seek evaluation and engage in care," said Loren Larsen, chief executive officer of Videra Health. "When 80% of newly diagnosed patients start care, it highlights the importance of routine screening and follow-up.”1
TDScreen is a free digital tool which uses advanced video analysis and machine learning to assess involuntary movement associated with tardive dyskinesia. The assessment takes only 5 minutes and is designed to complement a clinical evaluation. Using the tool can be done in-office or remotely, and is intended to inform treatment decisions. The company noted that TDScreen is not a complete diagnostic tool and does not replace evaluation by qualified healthcare providers.
"TDScreen has brought greater consistency and objectivity to how we screen for and monitor potential tardive dyskinesia across our practice," said Carmen Kosicek, PMHNP, chief executive officer and cofounder of Visionary Psychiatry.1 "By establishing a clear baseline and tracking changes over time, we are better equipped to identify when patients may need further evaluation and to have more informed discussions about their care," Kosicek added.
Tardive dyskinesia is a chronic and involuntary movement disorder that may develop after long-term use of antipsychotic medications. This disorder remains frequently underdiagnosed and unnoticed due to subtle early symptoms and inconsistent screening practices. Symptoms may be mistaken for anxiety, signs of aging, or other conditions, leading to delays in diagnosis and treatment.
With Tardive Dyskinesia Awareness Month in May, we highlight the importance of screening and assessment. Psychiatric Times’ editor-in-chief, John J. Miller, MD, emphasized “the first task is to master the differential diagnoses of any movement-related symptom, then assess functional impact.”2 He added, “once the diagnosis of TD has been made, perform a thorough assessment of the resulting functional impairment and work with your patient to find the outcomes that are most appropriate for them.”
References
1. New data shows AI video screening prompts clinical evaluation, with 80% of diagnosed patients receiving treatment. Press release. April 28, 2026. Accessed April 28, 2026.
2. Miller JJ. Tardive dyskinesia: treat functional impairment, not the AIMS score. Psychiatric Times. June 13, 2025.
Related Content
